Phase III goals met – yet Zealand shares fall

Despite meeting both primary endpoints in a Phase 3 trial of the obesity drug survodutide, Zealand Pharma’s shares fell sharply on Thursday.

By Anders Göransson

October 1, 2026 4:32 PM

Survodutide is a long-acting dual agonist that activates both glucagon and GLP-1 receptors. The drug candidate was discovered by Danish biotech Zealand Pharma and has been licensed to Boehringer Ingelheim, which is now responsible for its further development in Phase 3.

The trial evaluated the treatment’s efficacy in adults with obesity or overweight and type 2 diabetes.

1 month free trial

Get access to all content on Life Science Focus

No commitment or card information required

Try Life Science Focus now

Already a subscriber? Log In

Applies to personal subscription only.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.

Yes please, I would like to receive Life Science Focuss newsletter Read cookie and data policy.

Yes please, I would like to receive marketing, offers, surveys, etc. from Life Science Focus Read cookie and data policy.

{{ window.visitor.corporateClient.name }}

Corporate solution

{{ window.visitor.ipAccess.corporateClient.name }}

{{ window.visitor.corporateClient.name }}

Phase III goals met – yet Zealand shares fall

Phase III goals met – yet Zealand shares fall

Sanofi strikes another multibillion-dollar deal – four candidates in focus

Novo slashes Wegovy price in Sweden – “It makes sense”

Study finds key gut bacterium undetectable in one in three Swedish infants

€67.5m financing for Danish eyecare candidate

Swedish obesity challenger halts drug programme

Effektivare textigenkänning med AI för industriell automation

The Three Pillars of Clinical Evidence Under the IVDR — What Manufacturers Need to Know

High-pressure technology takes nanoprocessing from the lab to pharmaceutical production

From Strategy to Start-Up: Preparing Clinical Studies for Success

ZEISS Medical Days 2026: See all highlights in one compact recap video

Webinar – Is your AI software a medical device?

När varje millimeter räknas – exakt gasflödeskontroll i kompakt format

From diagnosis to treatment, ZEISS introduces innovations across ZEISS Retina Workflow

The IVDR Transition Is Not Over: Key Deadlines and Common Pitfalls

100 000 timmar av beprövad tillförlitlighet: KNF:s membranpumpar sätter en ny standard

Smörjfri rörelseteknik – så väljer du rätt lösning för din applikation

Organoid screening workflow with ZEISS Lightfield 4D